The Top 5 Biosimilar Articles for the Week of October 26

October 30, 2020

Here are the top 5 biosimilar articles for the week of October 26, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of October 26, 2020.

Number 5: Earnings fell overall for Biogen, although biosimilar revenues continued an upward climb and were up 13% for the third quarter of 2020.

Number 4:A trio of legal experts discuss Amy Coney Barrett's Supreme Court seat and how that might affect deliberations on the Affordable Care Act and the Biologics Price Competition and Innovation Act (BPCIA).

Number 3: The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story for the third quarter, although reference etanercept (Enbrel) sales have seen major erosion.

Number 2: Investigators from the University of Utah said they found no additional safety or clinical risks in a study of patients who were switched from originator infliximab to infliximab biosimilars.

Number 1: Investigators derived a set of recommendations for improving biosimilar use from 44 interviews with physicians, hospital pharmacists, nurses, patients (or their representatives), and regulators across Europe.

To read all of these articles and more, visit